PHOTOFRIN

Photofrin Adverse Events Reported to the FDA Over Time

How are Photofrin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Photofrin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Photofrin is flagged as the suspect drug causing the adverse event.

Most Common Photofrin Adverse Events Reported to the FDA

What are the most common Photofrin adverse events reported to the FDA?

Off Label Use	29 (5.05%)
Cholangitis	26 (4.53%)
Oesophageal Stenosis	16 (2.79%)
Post Procedural Complication	15 (2.61%)
Deep Vein Thrombosis	12 (2.09%)
Bronchial Obstruction	11 (1.92%)
Hypotension	9 (1.57%)
Sepsis	8 (1.39%)
Dyspnoea	7 (1.22%)
Neoplasm Recurrence	7 (1.22%)
Oesophageal Fistula	6 (1.05%)
	Show More
Pneumonia	6 (1.05%)
Blood Bilirubin Increased	5 (.87%)
Excessive Granulation Tissue	5 (.87%)
Gastrointestinal Necrosis	5 (.87%)
Pain	5 (.87%)
Photosensitivity Reaction	5 (.87%)
Pneumonia Aspiration	5 (.87%)
Respiratory Distress	5 (.87%)
Acute Respiratory Distress Syndrome	4 (.7%)
Atrial Fibrillation	4 (.7%)
Bronchopleural Fistula	4 (.7%)
Fatigue	4 (.7%)
Fluid Overload	4 (.7%)
General Physical Health Deteriorati...	4 (.7%)
Haemoglobin Decreased	4 (.7%)
Haemoptysis	4 (.7%)
Malignant Neoplasm Progression	4 (.7%)
Oesophageal Ulcer	4 (.7%)
Pancreatitis	4 (.7%)
Pericardial Effusion	4 (.7%)
Pleural Effusion	4 (.7%)
Post Procedural Haemorrhage	4 (.7%)
Procedural Complication	4 (.7%)
Pulmonary Embolism	4 (.7%)
Pulmonary Function Test Decreased	4 (.7%)
Asthenia	3 (.52%)
Bradycardia	3 (.52%)
Cardiac Arrest	3 (.52%)
Chest Pain	3 (.52%)
Death	3 (.52%)
Dysphagia	3 (.52%)
Dysphonia	3 (.52%)
Empyema	3 (.52%)
Facial Palsy	3 (.52%)
Gastrointestinal Haemorrhage	3 (.52%)
Haematemesis	3 (.52%)
Hypoxia	3 (.52%)
Idiopathic Thrombocytopenic Purpura	3 (.52%)
Lobar Pneumonia	3 (.52%)
Lower Respiratory Tract Inflammatio...	3 (.52%)
Mediastinitis	3 (.52%)
Multi-organ Failure	3 (.52%)
Odynophagia	3 (.52%)
Oesophageal Perforation	3 (.52%)
Pyrexia	3 (.52%)
Radiation Oesophagitis	3 (.52%)
Recurrent Cancer	3 (.52%)
Sunburn	3 (.52%)
Syncope	3 (.52%)
Therapeutic Response Decreased	3 (.52%)
Tracheo-oesophageal Fistula	3 (.52%)
Abdominal Distension	2 (.35%)
Aorto-oesophageal Fistula	2 (.35%)
Atrioventricular Block First Degree	2 (.35%)
Bladder Spasm	2 (.35%)
Blood Creatinine Increased	2 (.35%)
Blood Pressure Decreased	2 (.35%)
Bronchial Secretion Retention	2 (.35%)
Cardiac Tamponade	2 (.35%)
Cardio-respiratory Arrest	2 (.35%)
Cerebral Haematoma	2 (.35%)
Cerebral Haemorrhage	2 (.35%)
Chylothorax	2 (.35%)
Coagulopathy	2 (.35%)
Collapse Of Lung	2 (.35%)
Coma	2 (.35%)
Condition Aggravated	2 (.35%)
Dehydration	2 (.35%)
Depression	2 (.35%)
Dysuria	2 (.35%)
Flatulence	2 (.35%)
Haematuria	2 (.35%)
Haemorrhage	2 (.35%)
Haemothorax	2 (.35%)
Hepatic Necrosis	2 (.35%)
Hydrothorax	2 (.35%)
Infusion Related Reaction	2 (.35%)
International Normalised Ratio Incr...	2 (.35%)
Intra-abdominal Haemorrhage	2 (.35%)
Lethargy	2 (.35%)
Lung Neoplasm	2 (.35%)
Malaise	2 (.35%)
Malnutrition	2 (.35%)
Metastatic Neoplasm	2 (.35%)
Micturition Urgency	2 (.35%)
Myocardial Infarction	2 (.35%)
Necrosis	2 (.35%)
Neoplasm Progression	2 (.35%)
Oedema Mouth	2 (.35%)
Oedema Peripheral	2 (.35%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Photofrin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Photofrin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Photofrin

What are the most common Photofrin adverse events reported to the FDA?

Procedural And Device Related Injur...	31 (5.4%)
Infections - Pathogen Unspecified	30 (5.23%)
Respiratory	30 (5.23%)
Therapeutic Procedures And Supporti...	29 (5.05%)
Bile Duct	26 (4.53%)
Miscellaneous And Site Unspecified ...	20 (3.48%)
Gastrointestinal Stenosis And Obstr...	18 (3.14%)
Bronchial Disorders	16 (2.79%)
Urinary Tract Signs	16 (2.79%)
Cardiac Arrhythmias	14 (2.44%)
Embolism And Thrombosis	14 (2.44%)
	Show More
Pleural	14 (2.44%)
Epidermal And Dermal Conditions	12 (2.09%)
Gastrointestinal Conditions	12 (2.09%)
Lower Respiratory Tract Disorders	12 (2.09%)
Neurological	11 (1.92%)
Gastrointestinal Signs	10 (1.74%)
Decreased And Nonspecific Blood Pre...	9 (1.57%)
Gastrointestinal Hemorrhages	9 (1.57%)
Gastrointestinal Ulceration And Per...	9 (1.57%)
Hematology Investigations	8 (1.39%)
Hepatobiliary	8 (1.39%)
Injuries By Physical Agents	8 (1.39%)
Electrolyte And Fluid Balance Condi...	7 (1.22%)
Injuries	7 (1.22%)
Pericardial	7 (1.22%)
Hepatic And Hepatobiliary	6 (1.05%)
Cranial Nerve Disorders	5 (.87%)
Gastrointestinal Vascular Condition...	5 (.87%)
Oral Soft Tissue Conditions	5 (.87%)
Platelet	5 (.87%)
Skin And Subcutaneous Tissue	5 (.87%)
Tissue	5 (.87%)
Appetite And General Nutritional	4 (.7%)
Central Nervous System Vascular	4 (.7%)
Exocrine Pancreas Conditions	4 (.7%)
Gastrointestinal Neoplasms Malignan...	4 (.7%)
Pulmonary Vascular	4 (.7%)
Renal And Urinary Tract Investigati...	4 (.7%)
Respiratory And Mediastinal Neoplas...	4 (.7%)
Respiratory And Pulmonary Investiga...	4 (.7%)
Therapeutic And Nontherapeutic Effe...	4 (.7%)
Body Temperature Conditions	3 (.52%)
Fatal Outcomes	3 (.52%)
Neoplasm Related Morbidities	3 (.52%)
Renal Disorders	3 (.52%)
Respiratory Disorders Congenital	3 (.52%)
Upper Respiratory Tract Disorders	3 (.52%)
Vascular Inflammations	3 (.52%)
Administration Site Reactions	2 (.35%)
Arteriosclerosis, Stenosis, Vascula...	2 (.35%)
Bacterial Infectious	2 (.35%)
Cardiac And Vascular Investigations	2 (.35%)
Coagulopathies And Bleeding Diathes...	2 (.35%)
Coronary Artery	2 (.35%)
Depressed Mood Disorders	2 (.35%)
Gallbladder	2 (.35%)
Lifestyle Issues	2 (.35%)
Musculoskeletal And Connective Tiss...	2 (.35%)
Physical Examination Topics	2 (.35%)
Thoracic Disorders	2 (.35%)
Ureteric	2 (.35%)
Vascular	2 (.35%)
Vascular Hemorrhagic	2 (.35%)
Acid-base	1 (.17%)
Allergic Conditions	1 (.17%)
Anemias Nonhemolytic And Marrow Dep...	1 (.17%)
Aneurysms And Artery Dissections	1 (.17%)
Angiedema And Urticaria	1 (.17%)
Bladder And Bladder Neck Disorders	1 (.17%)
Bone And Joint Injuries	1 (.17%)
Bone, Calcium, Magnesium And Phosph...	1 (.17%)
Enzyme	1 (.17%)
Glaucoma And Ocular Hypertension	1 (.17%)
Heart Failures	1 (.17%)
Hematological	1 (.17%)
Hematological And Lymphoid Tissue T...	1 (.17%)
Hepatobiliary Therapeutic Procedure...	1 (.17%)
Immunology And Allergy	1 (.17%)
Joint	1 (.17%)
Leukemias	1 (.17%)
Metabolism	1 (.17%)
Microbiology And Serology	1 (.17%)
Movement Disorders	1 (.17%)
Muscle	1 (.17%)
Myocardial	1 (.17%)
Nervous System Neoplasms Malignant ...	1 (.17%)
Peritoneal And Retroperitoneal Cond...	1 (.17%)
Protein And Amino Acid Metabolism	1 (.17%)
Respiratory Tract Therapeutic Proce...	1 (.17%)
Tongue Conditions	1 (.17%)
Vascular Injuries	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Photofrin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Photofrin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.